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Genes encoding seven mammalian P2X receptor subtypes
(P2X1-7) have been identiﬁed and they assemble to form
homo- and hetero-trimeric ATP-gated channels with a range
of phenotypes (North 2002). P2X1 receptors are expressed
throughout the body and contribute to a range of physiolog-
ical processes, e.g. regulation of smooth muscle tone (Valera
et al. 1994; Scase et al. 1998; Sage et al. 2000) and
thrombosis (Hechler et al. 2003). In the nervous system
P2X1 receptors form heteromeric assemblies and are
involved in the pre-synaptic regulation of transmitter release
in the auditory brainstem (Watano et al. 2004) and a P2X1/5
heteromeric receptor has recently been described in astro-
cytes (Lalo et al. 2008).
P2X receptors constitute a distinct family of ligand gated
ion channels with intracellular amino and carboxy termini,
two transmembrane segments and a large extracellular loop
involved in drug action (Roberts et al. 2006). The intracel-
lular regions of the channels have been shown to be involved
in channel regulation (Boue-Grabot et al.2000; Jiang
et al.2001; Eickhorst et al.2002; Ennion and Evans 2002;
Chaumont et al. 2004; Vial et al. 2004). The amino termini
have a relatively standard length of about 30 amino acids
(North 2002). This contains a protein kinase C consensus
sequence TXK/R preceded by a conserved tyrosine giving
rise to a YXTXK/R motif (Tyr
16-Lys
20 in the P2X1 receptor)
that is conserved in all mammalian and Dictyostelim
receptors (Boue-Grabot et al. 2000; Fountain et al. 2007).
Mutations of the central threonine led to a speeding of
channel desensitization and reduction in peak current ampli-
tude (Boue-Grabot et al.2000; Ennion and Evans 2002) and
this residue may be constitutively phosphorylated (Liu et al.
2003). Furthermore, for the P2X2 receptor when the C-
terminal was truncated, the P2X2 receptor showed faster
desensitization, but the normal wild type time-course was
recovered by phorbol ester which stimulates PKC (Boue-
Grabot et al. 2000). Therefore, the N-terminus may be
involved in intracellular regulatory mechanisms.
P2X receptors can be regulated by G-protein coupled
receptors (GPCRs) (Ralevic and Burnstock 1998; Paukert
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Abstract
The potentiation of P2X1 receptor currents by phorbol ester
(PMA) treatment and stimulation of mGluR1a receptors was
sensitive to inhibition of novel forms of protein kinase C.
Potentiation was also reduced by co-expression of an amino
terminal P2X1 receptor minigene. Cysteine point mutants of
residues Tyr
16-Gly
30 were expressed in Xenopus oocytes.
Peak current amplitudes to ATP for Y16C, T18C and R20C
mutants were reduced, however this did not result from a
decrease in surface expression of the channels. The majority
of the mutants showed changes in the time-course of
desensitization of ATP evoked currents indicating the impor-
tant role of this region in regulation of channel properties. PMA
and mGluR1a potentiation was abolished for the mutants
Y16C, T18C, R20C, K27C and G30C. Minigenes incorporat-
ing either Y16C, K27C, V29C or G30C still inhibited PMA
responses. However D17C, T18C or R20C mutant minigenes
were no longer effective suggesting that these residues are
important for interaction with regulatory factors. These results
demonstrate that the conserved YXTXK/R sequence and a
region with a conserved glycine residue close to the ﬁrst
transmembrane segment contribute to PMA and GPCR reg-
ulation of P2X1 receptors.
Keywords: ATP, mutagenesis, P2X receptors, protein kinase
C, regulation.
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example P2X1 receptor currents can be potentiated by
mGluR1a, P2Y1, P2Y2 and 5-hydroxytryptamine (5-HT)2A
receptors as well as by phorbol ester (phorbol-12-myristate-
13-acetate, PMA) treatment and these effects were abolished
by the broad spectrum kinase inhibitor staurosporine (Vial
et al. 2004; Ase et al. 2005). This was independent of
phosphorylation of the consensus PKC site, as potentiation
was still seen when the conserved threonine residue was
mutated, and it has been suggested that the modulatory
effects may result from action on an interacting protein (Vial
et al. 2004). However amino acids in the P2X1 receptor that
contribute to the regulation were not determined.
In this study, we have investigated (i) the role of novel,
calcium insensitive, protein kinase C isoforms in the control
of the P2X1 receptor, (ii) the contribution of the N-terminus
of the P2X1 receptor in regulation using over-expression of a
minigene and (iii) used cysteine scanning of the 15 residues
before the ﬁrst transmembrane segment to identify for the
ﬁrst time residues involved in regulation of P2X1 receptors
by GPCRs and phorbol ester.
Methods
Minigene construction
The amino terminal sequence (Met
1-Gly
30) of the human P2X1
receptor was ampliﬁed from the pcDNA 3.0 vector containing the
human P2X1 receptor cDNA by Polymerase Chain Reaction (PCR)
(Techne Genius thermocycler, BioTAQ
TM DNA polymerase, Bio-
line, UK). Start and stop codons at the ends of the minigene as well
as restriction sites, EcoRI and HindIII, were introduced using the
primers. The minigene sequence was ligated into the plasmid
pcDNA3.0 using these two restriction sites at 14C overnight (T4
DNA ligase, New England Biolabs
 Inc., Hertfordshire, UK).
Site-directed mutagenesis
Point mutations were introduced into the human P2X1 plasmid or
the minigene construct using the QuikChange
TM mutagenesis kit
(Stratagene, Amsterdam, Netherlands) according to the manufac-
turer’s instructions as described previously (Ennion et al. 2000) and
conﬁrmed by DNA sequencing (Automated ABI Sequencing
Service, Leicester University, Leicester, UK).
Expression in xenopus laevis oocytes
The human mGluR1a receptor was a gift from Professor S. R.
Nahorski (University of Leicester, Leicester, UK). pcDNA3.1
vectors (Invitrogen, Paisley, UK) containing either P2X1 mutant,
wild-type P2X1, mGluR1a receptors or the N-termini minigene were
linearized. Sense-strand cRNAs were generated from these linear-
ized plasmids with the T7 mMessage mMachine
TM kit [Ambion
(Europe), Huntingdon, Cambs., UK].
Xenopus laevis oocytes, stage V, were prepared by enzymatic
treatment followed by manual defoliculation as described previously
(Ennion et al. 2000). 50 nL of mRNA (1 lg/lL) was injected into
isolated Xenopus oocytes using an Inject+Matic microinjector
(J.Alejandro Gaby, Geneva, Switzerland). For co-injections with
N-termini minigenes the RNA was mixed to give 5 ng wild type
(WT) P2X1 + 10 ng mGluR1a + 35 ng N-termini minigene (or
appropriate volume of water was added in the absence of minigene)
and injected in a 50 nL volume. Cells were maintained at 18Ci n
ND96 buffer (concentrations in mM; 96 NaCl, 2 KCl, 1.8 CaCl2,1
MgCl2, 5 sodium pyruvate and 5 HEPES, pH 7.5) with 50 lg/mL
gentamicin and were used for recording after 2–6 days.
Electrophysiological recordings
Two-electrode voltage clamp was used on cRNA-injected oocytes to
record currents to applied ATP (Mg salt; Sigma, Poole, UK) as
described previously (Ennion et al. 2000). ATP was applied with a
fast-ﬂow U-tube perfusion system, applications of ATP were
separated by 5 min in order to allow recovery from receptor
desensitization.
For oocytes pre-treated with PMA, 100 nM PMA was made in
ND96 solution and the oocytes were pre-incubated in the PMA
solution for 10 min at 21C immediately before recording.
Comparisons were made between groups of control untreated
oocytes and those exposed to PMA. The protein kinase inhibitors
Calphostin C(1 lM) (Sigma C6303), K252a (100 nM) (Sigma
05288), Go ¨6983(200 nM) (Sigma G1918) or Go ¨6976 (200 nM)
(Sigma G1171) were applied to the oocytes for 1 h at 21C before
recording. The inhibitors, when applied alone had no effect on the
peak current amplitude or the time-course of P2X1 receptor currents
(data not shown). When looking at the potentiation of the P2X1
receptor, glutamate (100 lM) with or without the protein kinase
inhibitors was bath-perfused for 5 min between the stimulations of
the P2X1 receptor by ATP via the U-tube as described previously.
The glutamate was applied to the oocytes when stable responses
were observed (Vial et al. 2004).
Western-blotting
The expression levels and molecular weight of the P2X receptor
proteins were estimated by western blotting, and both the level of
expressed total and cell surface P2X1 receptors were studied as
described previously (Ennion et al. 2000).
Data analysis
All data are shown as mean ± SEM Signiﬁcant differences between
the means of all groups compared to WT were calculated by one-
way ANOVA, followed by Dunnett’s test for comparisons of
individual mutants against control using the GraphPad Prism 5 for
Windows (GraphPad Software, San Diego, CA, USA). Student’s t
tests were also used where appropriate and considered to be
signiﬁcant when p < 0.05. n corresponds to the number of oocytes
tested for electrophysiological data.
Results
Novel protein kinase C isoforms contribute to regulation of
the P2X1 receptor by PMA and GPCRs
For oocytes co-expressing P2X1 and mGluR1a receptors
ATP (100 lM, a maximal concentration) evoked transient
inward currents that desensitised during the application of
ATP. P2X1 receptor currents were potentiated by 103.1 ±
11.8% (n = 19) following 10 min pre-treatment with PMA
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receptors by 100 lM glutamate for 5 min evoked a transient
inward calcium activated chloride current and potentiated the
subsequent responses of WT P2X1 receptors to ATP
(100 lM) by 61.0 ± 3.9% (n = 13) (Fig. 1). This is consis-
tent with our previous studies on the P2X1 receptor (Vial
et al. 2004). We have previously shown that these effects
could be reduced by treatment with the broad spectrum
kinase inhibitor staurosporine but were unlikely to involve
classical isoforms of protein kinase C as potentiation was not
calcium sensitive (Vial et al. 2004). To determine whether
novel, calcium insensitive, protein kinase C isoforms
(PKCd,e,g,h,o rl) are involved in the regulation we have
used a range of inhibitors (Fig. 1) [none of these had an
effect on peak P2X1 receptor current amplitude or time
course (data not shown)]. Calphostin C(1 lM) acts by
competing with the diacyl glycerol and phorbol ester binding
site of protein kinase C isoforms and reduced potentiation by
PMA and mGluR1a stimulation to 15.5 ± 13.9% (n =1 1 )
and 13.5 ± 2.8% (n = 5). Potentiation was also reduced by
the kinase inhibitor K252a (100 nM) (32.6 ± 10.0% and
20.3 ± 5.9%, n = 19, 5 respectively). Go ¨6983 is a kinase
inhibitor at novel PKCs d,e,g,h, but is ineffective at the
novel isoform PKCl (also called protein kinase D,
PKD)(Martiny-Baron et al. 1993). Potentiation was reduced
to )6.9 ± 12.4% (n = 13) and )2.8 ± 3.9% (n =7 ) b y
Go ¨6983 (200 nM) for PMA and mGlur1a respectively.
Go ¨6976 (200 nM) is an effective inhibitor of the novel
calcium insensitive protein kinase C isoform PKCl but is
ineffective at the other calcium insensitive novel PKC
isoforms (Gschwendt et al. 1996) and reduced PMA and
mGluR1a mediated potentiation to )3.2 ± 11.4% (n =8 )
and 27.6 ± 0.9% (n = 3). These ﬁndings are similar to those
reported for 5-HT dependent regulation of the receptor (Ase
et al. 2005) and suggest that novel protein kinase C isoforms
mediate P2X1 receptor regulation by both PMA and GPCRs.
However our previous studies showed that P2X1 receptor
current potentiation was unaffected by mutation to remove
the consensus PKC site, and a change in the phosphorylation
(a)
(b)
Fig. 1 Potentiation of P2X1 receptor currents by PMA and mGluR1a
receptor stimulation is sensitive to inhibitors of novel isoforms of pro-
tein kinase C. (a) Representative traces of currents evoked by ATP
(100 lM) under control conditions (left) and following treatment with
PMA (100 nM) or PMA following incubation with the PKC inhibitors
(1 h pre-incubation before 10 min of PMA) calphostin C (1 lM), K252a
(100 nM), Go ¨6983 (200 nM) or Go ¨6976 (200 nM). The lower panel
shows a summary of the effects of the inhibitors on PMA potentiation,
n = 5–19. (b) Sample traces of the effects of PKC inhibitors and
mGluR1a mediated potentiation of P2X1 receptor currents. Application
of glutamate (100 lM) evoked a transient inward calcium activated
chloride current and potentiated the subsequent ATP current. Poten-
tiation was reduced following pre-treatment of the oocytes with the
PKC inhibitors. The lower panel shows a summary of the effects, of
the inhibitors on glutamate potentiation, n = 3–13. ***p < 0.001.
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These results suggest that the potentiation is mediated by
phosphorylation of an interacting regulatory protein (Vial
et al. 2004).
The amino terminus of the P2X1 receptor is involved in
GPCR and phorbol ester regulation
To determine whether the intracellular amino terminus of the
P2X1 receptor contributes to receptor modulation we co-
expressed P2X1 receptors and mGluR1a receptors with a
minigene encoding the amino terminus of the P2X1 receptor.
P2X1 receptor amino terminal minigene expression had no
effect on the P2X1 receptor currents (peak current amplitudes
to 100 lM ATP of )6875 ± 298 nA and )6302 ± 304 nA,
for control and with the minigene respectively n = 6), or the
amplitude of glutamate evoked chloride currents ()4996 ±
807 nA and )4155 ± 1233 nA respectively) demonstrating
that the minigene does not regulate P2X1 or mGluR1a
receptor expression or activation (Fig. 2). However
co-expression of the amino terminal minigene reduced
potentiation by PMA from 128.5 ± 12.6% to 25.8 ± 2.6%
(p < 0001, n = 6, 7) and by mGluR1a receptor stimulation
from 52.5 ± 3.1% to 28.3 ± 3.3% (p < 0.001, n =6 , 7 )
(Fig. 2). This suggests that the amino terminus is important
in regulation and that the minigene may work by sequester-
ing regulatory factor(s) associated with the receptor.
Effects of point cysteine substitutions on basic P2X1
receptor properties
We used cysteine substitution mutagenesis to investigate the
contribution of the 15 amino acids before the ﬁrst trans-
membrane segment to channel properties. This region
includes the conserved YXTXK/R motif and SCAM (substi-
tuted cysteine accessibility method) analysis of P2X2 recep-
tors suggested that this part of the amino terminal may play a
role in channel function (Jiang et al. 2001). ATP (100 lM)
evoked fast desensitizing inward currents from all of the
mutants. There was no effect on the peak current amplitude
for 12 of the mutants (Fig. 3, Table 1) however responses
were reduced for mutants Y16C, T18C, and R20C (Fig. 3,
Table 1). Western blotting showed there was no obvious
difference in either total or surface expression levels for these
mutants compared to WT (Fig. 3) demonstrating that the
(a) 
(b)  minigene
Fig. 2 The N-termini P2X1 receptor minigene blocks the potentiating
effects of PMA and mGluR1a receptor stimulation on P2X1 receptor
currents. A minigene encoding the N-terminal sequence of the P2X1
receptor was co-expressed with wild type P2X1 and mGluR1a recep-
tors in the Xenopus oocytes. (a) Upper left panels show representative
currents evoked by a maximal concentration of ATP (100 lM, indi-
cated by bar) at control oocytes (WT P2X1) and those following 10 min
incubation with PMA (100 nM). Right upper panels show the effects of
co-expression of the amino terminal minigene (NH2 minigene) on the
effects of PMA. The bar chart shows summary data, n = 6–7. (b)
Upper panels show sample traces for a given oocyte co-expressing
P2X1 and mGluR1a receptors (left) or P2X1 receptors, mGluR1a
receptors and the P2X1 receptor amino terminal minigene (right tra-
ces). Responses to a maximal concentration of ATP (100 lM, indi-
cated by bar) are shown before and after the application of glutamate
(100 lM). Glutamate evoked an inward calcium activated chloride
current and potentiated subsequent ATP evoked responses. This
potentiation was reduced by co-expression of the P2X1 receptor
N-terminal minigene. The bar chart shows a summary of the data,
n = 6–7. ***p < 0.001.
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cies in receptor trafﬁcking.
There were no major changes in ATP potency at the mutant
receptors; 1 lM ATP, an  EC50 concentration at the WT
receptor, evoked between 30% and 70% of the maximum
current amplitudes for each of the mutants. The time-course
of desensitisation (time for the peak currents to 100 lMA T P
to decay to 50%) was unaffected for the mutants Y16C,
R20C, V24C, N26C and G30C. Gly
30 is conserved through-
out the mammalian and Dictyostelium families (Fountain
et al. 2007). However, it is interesting that mutation to
cysteine had no effect on the current amplitude of time-
course of P2X1 (this study) or P2X2 (Jiang et al. 2001)
receptor currents. This shows that the ﬂexibility associated
with the glycine residue is not essential for normal channel
function. For the remainder of the mutants, there were
signiﬁcant changes in time-course. Slowed desensitisation
was recorded for D17C, P19C, L23C and K28C; with D17C
responses slowed almost 6 fold (Fig. 3, Table 1). Faster
desensitisation was seen for the remainder of the mutants
with the greatest change seen for V22C with an  3 fold
speeding (greater than for T18C) in the decay of current
evoked during the continued presence of ATP but no effect
on peak current amplitude (see Fig. 3b, Table 1). Studies on
the P2X2 receptor showed for the majority of analogous
mutants (13/15) there was no effect on the time-course of the
response (Jiang et al. 2001). This may reﬂect that P2X2
receptor currents are relatively non-desensitising whereas for
the P2X1 receptor there is a rapid transition once the channel
is open to the desensitised state, and this is more sensitive to
disruption of the amino terminus.
Cysteine substitution can block PMA potentiation
WT P2X1 receptors were potentiated by 116.5 ± 14.5%
(n = 11) following 10 min application of PMA. A similar
level of potentiation was seen for the mutants P19C, V22C,
L23C, V24C, V25C, N26C and K28C. For M21C, poten-
tiation was reduced to about 50%, no potentiation was seen
for the mutants Y16C, D17C, T18C, R20C, V29C and G30C
(Fig. 4), and the responses were inhibited for mutant K27C.
These results suggest a cluster of residues comprising the
conserved YXTXK/R motif and those close to the ﬁrst
transmembrane segment of the P2X1 receptor are involved in
PMA regulation.
Mutant minigenes identify residues important in
interaction with regulatory factors
Cysteine mutants that reduced PMA potentiation could be
important for mediating the interaction with a regulatory
factor and/or important in conformational changes induced
by the regulatory factor. To address these roles we introduced
the individual cysteint mutants that reduced PMA potentia-
tion into the N terminal minigene. It was predicted that
mutation of residues in the minigene important for interaction
with regulatory factors/proteins would remove the inhibitory/
sequestering effect of the minigene. Minigenes expressing
the mutants D17C, T18C and R20C no longer inhibited the
PMA induced potentiation (Fig. 4) consistent with a role of
these residues in mediating interactions with regulatory
factors. It is unlikely that these effects result from the
disruption of the protein kinase C consensus in the minigene
as PMA is still effective at potentiating P2X1 receptors where
the consensus for phosphorylation has been mutated (Vial
et al. 2004, and this study). In contrast Y16C, K27C, V29C
(a) 
(b) 
(c) 
(d) 
Fig. 3 The basic properties of cysteine points mutants of the P2X1
receptor N-terminal. (a) ATP (100 lM) evoked rapidly desensitising
responses at WT P2X1 receptors. Desensitising responses were also
recorded for the mutants Y16C, T18C and R20C however these were
of reduced amplitude. For T18C an insert is provided showing at an
increased scale the time-course of the ATP evoked response. (b)
Peak current normalised traces showing the more rapid (V22C) and
slower (D17C) rates of channel desensitisation of ATP evoked re-
sponses compared to WT. (c) Peak current amplitudes of WT and
P2X1 receptor mutants to ATP (100 lM). ***p < 0.001. (d) Surface and
total expression levels of WT and mutant P2X receptors with reduced
peak current amplitudes.
 2008 The Authors
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and suggested that these residues may be important in
conformational changes on the P2X1 receptor associated with
PMA potentiation.
Differential sensitivity of cysteine mutants to mGluR1a
receptor and PMA
For the mutants where PMA no longer had an effect or
reduced the response, we also tested to see whether
mGluR1a receptor dependent regulation was also attenuated.
ATP (100 lM) was applied repeatedly at 5 min intervals to
obtain reproducible responses. Glutamate potentiated WT
P2X1 receptor currents by 67.8 ± 4.8% (n = 8). For most (4/
6) of the mutants that showed no potentiation with PMA
treatment the effects of mGluR1a receptor stimulation were
also reduced signiﬁcantly (Fig. 5). However, the mGluR1a
receptor regulation was not affected by the mutations D17C
and V29C (that abolished PMA potentiation) where the
application of glutamate gave potent potentiations of
114.5 ± 4.7% (n = 4) and 66.2 ± 6.9% (n = 5) respectively.
These results demonstrate that PMA and mGluR1a stimu-
lation have some differences in their regulatory mechanisms.
Substitution dependence on residues compromising the
consensus PKC site
The consensus PKC motif (TXR/K) is conserved on the N-
terminus of P2X receptors. When this consensus was
disrupted (R20A) comparable potentiation by GPCRs to
the WT P2X1 receptor was observed (Vial et al. 2004). As
the R20C mutant exhibited a dramatic reduction to the effect
of mGluR1a receptor stimulation we have determined the
effect of different substitutions at residue Arg
20. Following
Table 1 Summary of basic properties of P2X1 receptor cysteine mu-
tants
P2X1
receptor
Peak response
at 100 lM ATP (nA)
100–50% decay
time (ms)
WT )6513 ± 179 258 ± 7
Y16C )1297 ± 93*** 232 ± 13
D17C )9361 ± 429*** 1501 ± 12***
T18C )52 ± 4*** 146 ± 10***
P19C )7302 ± 235 1070 ± 20***
R20C )4153 ± 273*** 244 ± 4
M21C )6962 ± 389 409 ± 13***
V22C )5605 ± 255 87 ± 6***
L23C )6698 ± 41 528 ± 20***
V24C )7147 ± 265 284 ± 11
R25C )5950 ± 419 165 ± 9***
N26C )6039 ± 319 241 ± 12
K27C )7182 ± 279 339 ± 26*
K28C )6921 ± 113 666 ± 21***
V29C )5849 ± 277 169 ± 4***
G30C )7190 ± 232 242 ± 10
The peak current amplitude and the decay time from 100% to 50% of
the peak current are summarized for the WT P2X1 receptor and the
cysteine mutants (n = 4–21). *p < 0.05, ***p < 0.001.
(a) 
(b) 
(c) 
Fig. 4 PMA potentiation can be abolished by cysteine substitution of
amino terminal residues. (a) Sample traces of ATP evoked currents
(100 lM application indicated by bar) from oocytes under control
conditions and following PMA (100 nM) treatment for WT as well as
the mutants D17C, N26C and K27C. (b) Summary of the percentage
changes of peak amplitudes by PMA treatment for N-termini cysteine
mutants. Cysteine mutants around the conserved PKC consensus site
and next to the ﬁrst transmembrane segment were no longer poten-
tiated by PMA. (c) Effects of mutations of the minigene on PMA
potentiation. **p < 0.01, ***p < 0.001.
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potentiation as for WT receptors were seen for R20A and
R20I mutants following application of glutamate (100 lM)
(Fig. 6). However in all cases (R20C, R20A and R20I), the
effects of PMAwere abolished (Fig. 6). These results further
highlight differences between PMA and mGluR1a mediated
regulation. A dependence of the nature of the amino acid
substituted was also shown at position Thr
18. The mutant
T18C blocked the PMA ()0.2 ± 10.5%, n = 4) regulation of
the P2X1 receptor, while the T18A mutation had no effect on
PMA potentiation (194.7 ± 18.8%, n = 7). These results
demonstrate the effects of mutations that remove the
consensus PKC motif are dependent on the amino acid
substitution and suggest it is the local amino acid environ-
ment, and not the ability to be phosphorylated that regulates
channel function in this region.
(b) 
(a) 
Fig. 5 The effects of mGluR1a receptor activation on P2X1 receptor
mutants. (a) Sample traces for a given oocyte co-expressing either WT
P2X1, D17C or K27C mutant P2X1 receptor with mGluR1a receptors.
Responses to a maximal concentration of ATP (100 lM, indicated by
bar) are shown before and after the application of glutamate (dotted
line). Glutamate (100 lM) evoked an inward calcium activated chloride
current and potentiated subsequent ATP evoked responses for WT
and D17C mutants but not for the K27C mutant P2X1 receptor. (b) The
effects of mGluR1a receptor (100 lM glutamate) and PMA (100 nM)
on WT and the cysteine mutants are shown (+++p < 0.001 comparing
mGluR1 receptor regulation of mutants to WT, ***p < 0.001 for mu-
tants treated with PMA compared to the WT effect). For most of the
mutants unable to exhibit the PMA potentiation, no potentiation was
seen following the activation of mGluR1a receptor. However, the
mGluR1a receptor stimulated potentiation was still robust for the D17C
and V29C mutants.
(a)
(b)
Fig. 6 The effects of PMA and mGluR1a receptor to R20 substitu-
tions. (a) Example traces of R20C and R20A mutants in response to
PMA (100 nM) or mGluR1a receptor stimulation (100 lM glutamate)
are shown. Peak amplitudes from control and PMA treated oocytes
are shown. In the lower panels ATP evoked currents before and after
mGluR1a receptor activation from either R20C (left) or R20A (right)
are shown. (b) Summary of effects of amino acid substitution at po-
sition R20 at the P2X1 receptor by cysteine, alanine or isoleucine on
potentiation by PMA or glutamate. ***p < 0.001.
 2008 The Authors
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The permeability of some P2X receptors changes with time
(Khakh et al. 1999; Virginio et al. 1999) and can lead to an
increase in currents for the P2X4 receptor (Khakh et al.
1999). TRPV1 receptors show a similar change in perme-
ability on prolonged agonist application and this is poten-
tiated by activation of PKC (Chung et al. 2008). We tested
whether the potentiation in current at the P2X1 receptor
following PMA treatment resulted from an increase in
permeability. Under control conditions when dimethylamine
was the only external cation P2X1 receptor currents reversed
at )10.2 ± 0.9 mV (n = 5) (consistent with previous studies
on the receptor, Evans et al. 1996). The reversal potential for
dimethylamine was unaffected ()11.1 ± 1.9 mV, n =8 )
following PMA treatment demonstrating that the potentiation
of P2X1 receptor currents does not result from an increase in
channel permeability.
Discussion
P2X1 receptor mediated responses can be potentiated by
phorbol ester and Gaq coupled GPCR stimulation and this
may allow for regulation of P2X receptor signalling (Vial
et al. 2004). The > 80% reduction by calphostin C of P2X1
receptor potentiation by PMA or mGluR1a stimulation
supports the role of protein kinase C in receptor regulation.
Our previous study showed that potentiation was not
dependent on a rise in intracellular calcium (Vial et al.
2004) and suggests that novel, calcium insensitive, and not
classical calcium sensitive PKC isoforms are involved.
Amongst the novel PKC isoforms Go ¨6976 is selective for
PKCl (PKD) and abolished potentiation by PMA and
reduced by  60% mGluR1a modulation. This indicates a
role of PKCl (PKD) in the regulation of P2X1 receptors, as
reported previously for 5-HT regulation (Ase et al. 2005).
The difference in effectiveness of the PKCl inhibitor
between PMA and mGluR1a stimulation suggests that there
are differences in the regulatory pathways used. This is
consistent with mutagenesis studies that showed D17C and
V29C mutants abolished PMA potentiation but had no effect
on the mGluR1a stimulation. In addition the minigene had a
greater inhibitory effect on PMA stimulation than on that
evoked by mGluR1a stimulation even though the extent of
PMA potentiation at  120% was signiﬁcantly higher that
the  55% potentiation evoked by mGluR1a stimulation.
This suggests that mGluR1a stimulation recruits additional
regulatory pathways compared to PMA. The reduction in
potentiation by Go ¨6983 (effective at the concentration used
at novel PKC isoforms with the exception of PKCl;I C 50 100
times higher than that used in the current study) suggests that
one or more of the isoforms PKC d,e,g, h are also involved.
mGluR1a potentiation was still observed when the proposed
‘phosphorylatable’ threonine was mutated or the consensus
PKC sequence was disrupted by Arg
20 mutation (this study
and Vial et al. 2004). In addition we could not detect any
changes in P2X1 receptor phosphorylation on PMA stimu-
lation and studies on the P2X3 receptor also failed to detect
receptor phosphorylation associated with PKC regulation
(Franklin et al. 2007). These studies rule out a role of
phosphorylation at the consensus PKC site as a mechanism
of action and raise the question where the novel PKC
isoforms act? Interacting proteins that regulate the function
of P2X7 and P2X2 receptors have been described (Adinolﬁ
et al. 2003; Masin et al. 2006) and we suggest that
modulation of the P2X1 receptor occurs through the phos-
phorylation by a novel PKC of a regulatory protein that
interacts with the P2X1 receptor.
Minigenes have been used widely to study regulation (Del
Gatto et al. 1996; Wu et al. 2004) including work on P2X
receptors (Boue-Grabot et al. 2000). The over-expression of
a minigene encoding the amino terminus of the P2X1
receptor reduced PMA and mGluR1a receptor potentiation
of P2X1 receptor currents and demonstrated that the amino
terminus plays an important role in receptor regulation
possibly through providing a docking site for a regulatory
protein and therefore over-expression of the minigene led to
sequestering of this regulatory protein. The minigene, like
the range of PKC inhibitors used, had no effect on the P2X1
receptor currents under resting conditions suggesting that the
receptor is not basally regulated, and that PMA and GPCR
stimulation provide an auxiliary mechanism to modify
channel properties. The greater reduction on the PMA effect
compared to GPCR stimulation by the amino terminal
minigene suggests that GPCR stimulation could have
additional regulatory effects (and is consistent with mutations
that abolish PMA effects with little action on mGluR1a
stimulation). These results also suggest that the C terminus
may also play a signiﬁcant role in the regulation of the P2X1
receptor (this is supported by studies with a C terminal
minigene H. W. and R. J. E., unpublished observations). In
addition the abolition of PMA potentiation by the mutations
D17C, R20A and V29C but no effect on mGlur1a stimu-
lation indicates further that there are subtle differences in the
regulation following PMA and mGlur1a stimulation, how-
ever the molecular basis of this remains to be elucidated.
The cysteine mutagenesis of the P2X1 receptor amino
terminal identiﬁed residues that were important for PMA
regulation. The introduction of these mutants into the
minigene in a second round of mutagenesis identiﬁed
substitutions that abolished the inhibitory effect of the
minigene (D17C, T18C and R20C) and those that had no
effect on the inhibitory actions of the minigene (Y16C,
K27C, V29C and G30C). The abolition of the inhibitory
effect of the minigene when Asp
17, Thr
18 or Arg
20 were
mutated demonstrates that these residues are likely to play an
important role in the sequestering action of the minigene in
competing with the P2X1 receptor for the regulatory factor/
protein and identiﬁes for the ﬁrst time residues that involved
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results with the minigene also show that resides Tyr
16,L y s
27,
Val
29 and Gly
30 are not important in the interaction directly
with the regulatory factor but mediate the changes in the P2X1
receptor that lead to potentiation of the response. One
possibility is that these residues could contribute to the gating
of the P2X1 receptor or regulation of channel conductance.
Responses at the Y16C, P19C and G30C mutants were
reduced by cysteine reactive MTS reagents for the P2X1 (see
Fig. S1; Appendix S1) and this is consistent with the ﬁndings
for the P19C and G30C mutants at the P2X2 receptor (Y16C
mutant was non-functional see above) (Jiang et al. 2001). In
previous studies we have shown that MTS reagents that result
in a change in ATP potency at P2X1 receptors modify the
time-course of the currents (Roberts and Evans 2007). The
reduction in amplitude by MTSEA of Y16C, P19C and G30C
mutant P2X1 receptors with no effect on the time-course of
the response suggests that these residues are involved in ionic
permeation through the channel. Taken together these results
give rise to amechanism whereby following PMAstimulation
Asp
17, Thr
18 and Arg
20 are involved in interaction with a
regulatory factor that is phosphorylated,and this subsequently
results in a change in channel properties involving residues
Tyr
16,L y s
27,V a l
29 and Gly
30.
In summary this study has identiﬁed two amino terminal
regions, YXTXK/R and Lys
27-Gly
30 that are involved in
regulation by PMA and ionic permeation. This raises the
possibility that there may be some interaction between these
two regions to regulate channel properties. Structural models
of the intracellular regions however will be required for fuller
interpretation of these results.
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